In use product safety assessment report for infliximab biosimilars

The availability of seven infliximab preparations (the intravenous originator, four intravenous biosimilars and two subcutaneous products) in the UK market creates a potential for confusion in the prescribing, dispensing, and administration of these products.  This UKMi Product Safety assessment summarises practical in-use safety considerations associated with the use of infliximab products: Flixabi®, Inflectra®, Remsima® intravenous, Remsima subcutaneous, Zessly®. Potential next steps and mitigation actions are suggested.

UKMi Product Safety assessments are produced using the validated UKMi product assessment tool.